索引超出了数组界限。 文章摘要
|本期目录/Table of Contents|

[1]张侃迪,刘东升,张俊峰.射血分数保留型心力衰竭的药物治疗进展[J].国际心血管病杂志,2021,01:5-8.
点击复制

射血分数保留型心力衰竭的药物治疗进展(PDF)

《国际心血管病杂志》[ISSN:1006-6977/CN:61-1281/TN]

期数:
2021年01期
页码:
5-8
栏目:
综述
出版日期:
2021-01-20

文章信息/Info

Title:
-
作者:
张侃迪; 刘东升; 张俊峰
201900 上海交通大学医学院附属第九人民医院心内科
Author(s):
-
关键词:
心力衰竭;  射血分数保留;  射血分数减低
Keywords:
-
分类号:
-
DOI:
10.3969/j.issn.1673-6583.2021.01.002
文献标识码:
-
摘要:
射血分数保留型心力衰竭(HFpEF)是心力衰竭的一种特殊类型,尚缺乏确切有效的特异性治疗药物或方法,目前主要采用经验性治疗。该文主要介绍HFpEF的药物治疗新进展.
Abstract:
-

参考文献/References

[1] 胡盛寿, 高润霖, 刘力生, 等. 《中国心血管病报告2018》概要[J]. 中国循环杂志, 2019, 34(3):209-220
[2] Savarese G, Lund LH. Global public health burden of heart failure[J]. Card Fail Rev, 2017, 3(1):7-11
[3] Poppe KK, Squire IB, Whalley GA, et al. Known and missing left ventricular ejection fraction and survival in patients with heart failure: a maggic meta-analysis report[J]. Eur J Heart Fail, 2013, 15(11):1220-1227.
[4] Singh A, Mehta Y. Heart failure with preserved ejection fraction(HFpEF): implications for the anesthesiologists[J]. J Anaesthesiol Clin Pharmacol, 2018, 34(2):161-165.
[5] Leung CC, Moondra V, Catherwood E, et al. Prevalence and risk factors of pulmonary hypertension in patients with elevated pulmonary venous pressure and preserved ejection fraction[J]. Am J Cardiol, 2010, 106(2):284-286.
[6] Melenovsky V, Hwang SJ, Lin G, et al. Right heart dysfunction in heart failure with preserved ejection fraction[J]. Eur Heart J, 2014, 35(48):3452-3462.
[7] Redfield MM, Chen HH, Borlaug BA, et al. Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial[J]. JAMA, 2013, 309(12):1268-1277.
[8] Opitz CF, Hoeper MM, Gibbs JS, et al. Pre-capillary, combined, and post-capillary pulmonary hypertension: a pathophysiological continuum[J]. J Am Coll Cardiol, 2016, 68(4):368-378.
[9] Willette RN, Anderson KM, Nelson AH, et al. Enrasentan improves survival, limits left ventricular remodeling, and preserves myocardial performance in hypertensive cardiac hypertrophy and dysfunction[J]. J Cardiovasc Pharmacol, 2001, 38(4):606-617.
[10] Packer M, McMurray JJV, Krum H, et al. Long-term effect of endothelin receptor antagonism with bosentan on the morbidity and mortality of patients with severe chronic heart failure: primary results of the enable trials[J]. JACC Heart Fail, 2017, 5(5):317-326.
[11] Zile MR, Bourge RC, Redfield MM, et al. Randomized, double-blind, placebo-controlled study of sitaxsentan to improve impaired exercise tolerance in patients with heart failure and a preserved ejection fraction[J]. JACC Heart Fail, 2014, 2(2):123-130.
[12] Pieske B, Patel MJ, Westerhout CM, et al. Baseline features of the victoria(vericiguat global study in subjects with heart failure with reduced ejection fraction)trial[J]. Eur J Heart Fail, 2019, 21(12):1596-1604.
[13] Armstrong PW, Pieske B, Anstrom KJ, et al. Vericiguat in patients with heart failure and reduced ejection fraction[J]. N Engl J Med, 2020, 382(20):1883-1893.
[14] Pieske B, Maggioni AP, Lam CSP, et al. Vericiguat in patients with worsening chronic heart failure and preserved ejection fraction: results of the soluble guanylate cyclase stimulator in heart failure patients with preserved ef(socrates-preserved)study[J]. Eur Heart J, 2017, 38(15):1119-1127.
[15] Ambrosio G, Carluccio E, Ferratini M. The neat-hfpef study[J]. G Ital Cardiol(Rome), 2017, 18(2):87-91.
[16] Komajda M, Isnard R, Cohen-Solal A, et al. Effect of ivabradine in patients with heart failure with preserved ejection fraction: the edify randomized placebo-controlled trial[J]. Eur J Heart Fail, 2017, 19(11):1495-1503.
[17] Pitt B, Pfeffer MA, Assmann SF, et al. Spironolactone for heart failure with preserved ejection fraction[J]. N Engl J Med, 2014, 370(15):1383-1392.
[18] Pfeffer MA, Claggett B, Assmann SF, et al. Regional variation in patients and outcomes in the treatment of preserved cardiac function heart failure with an aldosterone antagonist(topcat)trial[J]. Circulation, 2015, 131(1):34-42.
[19] Solomon SD, McMurray JJV, Anand IS, et al. Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction[J]. N Engl J Med, 2019, 381(17):1609-1620.
[20] McMurray JJV, Jackson AM, Lam CSP, et al. Effects of sacubitril-valsartan versus valsartan in women compared with men with heart failure and preserved ejection fraction: insights from paragon-hf[J]. Circulation, 2020, 141(5):338-351.
[21] Cunningham JW, Vaduganathan M, Claggett BL, et al. Effects of sacubitril/valsartan on n-terminal pro-b-type natriuretic peptide in heart failure with preserved ejection fraction[J]. JACC Heart Fail, 2020, 8(5):372-381.
[22] Kosiborod M, Lam CSP, Kohsaka S, et al. Cardiovascular events associated with sglt-2 inhibitors versus other glucose-lowering drugs: the cvd-real 2 study[J]. J Am Coll Cardiol, 2018, 71(23):2628-2639.
[23] McMurray JJV, DeMets DL, Inzucchi SE, et al. A trial to evaluate the effect of the sodium-glucose co-transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction(dapa-hf)[J]. Eur J Heart Fail, 2019, 21(5):665-675.
[24] Vieira JL, Mehra MR. Dapagliflozin in patients with heart failure and reduced ejection fraction[J]. N Engl J Med, 2020, 382(10):972-973.
[25] Park JJ, Park CS, Mebazaa A, et al. Characteristics and outcomes of hfpef with declining ejection fraction[J]. Clin Res Cardiol, 2020, 109(2):225-234.
[26] Ge J. Coding proposal on phenotyping heart failure with preserved ejection fraction: a practical tool for facilitating etiology-oriented therapy[J]. Cardiol J, 2020, 27(1):97-98.

备注/Memo

备注/Memo:
通信作者:张俊峰,E-mail:jfzhang_dr@163.com
更新日期/Last Update: 2021-01-20